期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 13, 期 4, 页码 623-631出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.1c00685
关键词
Adenosine receptor; G-protein-coupled receptor; antagonist; molecular dynamics; radioligand
资金
- Astrocyte Pharmaceuticals (NIDDK) [CRADA 15-8056]
- NIH Intramural Research Program (NIDDK) [ZIADK031117]
- National Institutes of Health (NHLBI) [HL133589]
- National Institute of Mental Health's Psychoactive Drug Screening Program [HHSN-2712008-00025-C]
The structure-activity relationship of an A3AR antagonist has been explored and a high-affinity radioligand has been developed, which shows promise as a useful tool for receptor characterization and drug discovery.
The A3 adenosine receptor (A3AR) is a target forpain, ischemia, and inflammatory disease therapy. Among theligand tools available are selective agonists and antagonists,including radioligands, but most high-affinity non-nucleosideantagonists are limited in selectivity to primate species. We haveexplored the structure-activity relationship of a previouslyreported A3AR antagonist DPTN9(N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]nicotinamide) for radiolabeling, in-cluding 3-halo derivatives (3-iodo, MRS7907), and characterized9as a high -affinity radioligand [3H]MRS7799. A3ARKdvalues were(nM): 0.55 (human), 3.74 (mouse), and 2.80 (rat). An extendedmethyl acrylate (MRS8074,19) maintained higher affinity (18.9 nM) than a 3-((5-chlorothiophen-2-yl)ethynyl) derivative20.Compound9had an excellent brain distribution in rats (brain/plasma ratio similar to 1). Receptor docking predicted its orthosteric sitebinding by engaging residues that were previously found to be essential for AR binding. Thus the new radioligand promises to be auseful species-general antagonist tracer for receptor characterization and drug discovery
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据